For The Better

This online banking provider might be on your watch list thanks to strong recent financial results.

The industrial conglomerate looks like a great value, but there’s near-term risk around it.

Fisker Automotive is realizing weaker customer demand now that it has ramped up production and deliveries.

Two of 2023’s best performers still have plenty of upside ahead.

Leading business development company Ares Capital’s dividend currently yields roughly 10%.

The yields on these two beverage giants have risen this year as investors focus more on growth stocks.

Investors have soured on this competitively advantaged business.

Shares have more room to run from here.

The S&P 500 is a proven path to long-term returns, but there’s a better bet right now.

In seven years, America’s robot navy has quadrupled in size.

The AI-powered consumer lender stock is down 94% from its high. Should you hit the buy button?

I might have missed the boat the first time around, but I won’t pass up the opportunity the next time it presents itself.

New information about a key advertising deal in Apple’s services segment recently came to light.

Target has its work cut out for it.

This multifamily lender has pulled back 45% from its all-time high and looks like a solid buy ahead of a new bull market.

The once-hot IPO stock has cooled off.

Going through these steps can ensure investors are well-equipped with the information they need to make an informed decision.

This industry disruptor just went on sale, and I know a bargain when I see one.

Eli Lilly just received FDA approval for its obesity medication Zepbound, the sister treatment to its blockbuster drug Mounjaro.

The digital banking provider is standing out in a crowded industry.